JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Identification of ETV5 as a prognostic marker related to epigenetic modification in pan-cancer and facilitates tumor progression in hepatocellular carcinoma

  • 0Department of Medical Genetics and Developmental Biology, School of Medicine, The Key Laboratory of Developmental Genes and Human Diseases, Ministry of Education, Southeast University, Nanjing, 210009, China.
Scientific Reports +

|

November 29, 2024

|

November 29, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

ETS variant transcription factor 5 (ETV5) drives cancer progression and impacts patient prognosis and drug sensitivity across multiple malignancies. Its regulation of EZH2 highlights potential therapeutic targets for epigenetic cancer therapy.

Area Of Science

  • Oncology
  • Molecular Biology
  • Epigenetics

Background

  • ETS variant transcription factor 5 (ETV5) is a key developmental regulator with implicated roles in cancer.
  • Understanding ETV5's pan-cancer regulatory mechanisms is crucial for targeted therapies.

Purpose Of The Study

  • To systematically analyze ETV5's role in pan-cancer, including its association with prognosis, drug sensitivity, and epigenetic modifications.
  • To elucidate the molecular mechanisms of ETV5 in tumorigenesis, particularly in hepatocellular carcinoma.

Main Methods

  • Integrated data mining of RNA sequencing and clinical data from TCGA and GTEx databases.
  • Analysis of ETV5 expression correlations with patient outcomes, drug sensitivity, and epigenetic modulators like EZH2.
  • Experimental validation of ETV5's function in cell proliferation and drug response in hepatocellular carcinoma models.

Main Results

  • Highly expressed ETV5 correlates with unfavorable prognosis and altered drug sensitivity in multiple cancers.
  • ETV5 expression is linked to epigenetic modulators, notably EZH2.
  • ETV5 promotes cell proliferation and reduces sensitivity to GSK126 by regulating EZH2 in hepatocellular carcinoma, impacting tumor stage and patient outcomes.

Conclusions

  • ETV5 plays a significant carcinogenic role across various cancers, influencing prognosis and therapeutic responses.
  • ETV5's interaction with EZH2 offers a potential target for epigenetic-based cancer therapies.
  • This study provides a basis for ETV5-targeted diagnostics and therapeutics, including epigenetic drug development.

Keywords: